Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ARG1 | P05089 | 5/20 | 0.37 |
| ▸ | ARG2 | P78540 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23273791 | 1.00 | SLC1A2 (0.47) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL199007 | 1.00 | SLC1A2 (0.47) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL6861146 | 0.82 | CHRM2 (0.33) | SLC1A2 | |
| SCHEMBL10680722 | 0.79 | SLC1A2 (0.52) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL7280336 | 0.79 | SLC1A2 (0.52) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL7348716 | 0.79 | SLC1A2 (0.52) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL7346916 | 0.79 | SLC1A2 (0.52) | SLC1A2MEN1BLMKMT2AARG1 | |
| Hydrochloric Acid SCHEMBL26117737 | 0.77 | SLC1A2 (0.50) | SLC1A2MEN1BLMKMT2AARG1 | |
| Hydrochloric Acid SCHEMBL202139 | 0.77 | SLC1A2 (0.50) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL6863810 | 0.76 | SLC1A2 (0.48) | SLC1A2MEN1BLMKMT2AARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021081110-A2 | PEPTIDES AND USE THEREOF | ANEXIGEN, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-7199125-B2 | Spiro-cyclic compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050119279-A1 | Spiro-cyclic compounds useful as anti-inflammatory agents | CEREP SA (FR) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119279-A1 | Spiro-cyclic compounds useful as anti-inflammatory agents | CCR9, MSR1, CCR3 | SLC1A2 4858/4885MEN1 3170/4885BLM 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.